Timing is everything: new trial aims to save lives from immune storm
NCT ID NCT07497438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two strategies for starting the drug etoposide in adults with severe hemophagocytic lymphohistiocytosis (HLH) who are in the intensive care unit. HLH is a life-threatening overreaction of the immune system that can cause organ failure. The goal is to see if giving etoposide early, when organ failure first appears, reduces worsening organ damage compared to waiting to see if other treatments work first. About 176 participants will be randomly assigned to one of the two approaches.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Intensive Care Unit - Avicenne Hospital, Assistance Publique des Hôpitaux de Paris
Bobigny, 93000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Suicide Gene-Equipped t cells aim to make stem cell transplants safer
- Engineered t cells with a kill switch aim to make stem cell transplants safer
- Massive study tracks hidden toll of rare immune diseases
- Could a common vitamin a drug tame a deadly immune storm?
- Gentler transplant shows promise for kids with blood diseases
- Milder stem cell transplant shows promise for kids with immune disorders